<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04567368</url>
  </required_header>
  <id_info>
    <org_study_id>TB042</org_study_id>
    <nct_id>NCT04567368</nct_id>
  </id_info>
  <brief_title>TB-CAPT MTB/XDR Study</brief_title>
  <official_title>Two-site Laboratory-based Diagnostic Accuracy and Feasibility Study of the Xpert MTB/XDR Assay for Detection of Isoniazid, Fluoroquinolone, Ethionamide and Second-line Injectable Anti-tuberculosis Drug Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Innovative New Diagnostics, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wits Health Consortium (Pty) Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale San Raffaele</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss Tropical &amp; Public Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>African Society for Laboratory Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation for Innovative New Diagnostics, Switzerland</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Cepheid Xpert MTB/XDR cartridge, which runs on the same platform as Xpert MTB/RIF Ultra,&#xD;
      has been developed to detect additional resistance to isoniazid, fluoroquinolones and&#xD;
      second-line injectable anti-tuberculosis drugs and provides results within 2 hours and on&#xD;
      primary samples. An evaluation of the the Xpert MTB/XDR assay is currently underway in&#xD;
      clinical settings in South Africa, India and Moldova. The TB-CAPT MTB/XDR Study will add&#xD;
      further diagnostic accuracy and feasibility data to the evidence base for the Xpert MTB/XDR&#xD;
      assay.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 14, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of Xpert MTB/XDR assay</measure>
    <time_frame>enrolment</time_frame>
    <description>Sensitivity and specificity of Xpert MTB/XDR assay vs. the composite reference standard for detection of resistance to Isoniazid, Fluoroquinolones, Ethionamide, Second-line injectable anti-tuberculosis drugs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of Xpert MTB/XDR assay compared to phenotypic anti-tuberculosis drug susceptibility testing and WGS separately</measure>
    <time_frame>enrolment</time_frame>
    <description>Sensitivity and specificity of Xpert MTB/XDR assay for detection of resistance to Isoniazid, Fluoroquinolones, Ethionamide, Second-line injectable anti-tuberculosis drugs compared to phenotypic anti-tuberculosis drug susceptibility testing and WGS separately</description>
  </secondary_outcome>
  <enrollment type="Anticipated">753</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Resistance Bacterial</condition>
  <condition>Diagnoses Disease</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Xpert MTB/XDR</intervention_name>
    <description>Cepheid Xpert MTB/XDR assay for detection of resistance to INH, FQ and SLID</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Respiratory specimens testing rifampicin-resistant Mtb positive on Xpert MTB/RIF Ultra.&#xD;
&#xD;
        The proposed study procedures would not affect the usual care of patients as we will&#xD;
        utilise specimens that would ordinarily be discarded. Similarly, the reference standard&#xD;
        tests (next generation sequencing) are non-routine tests not currently utilised for patient&#xD;
        care in South Africa. These tests will be performed post hoc with patient identifiers&#xD;
        removed.&#xD;
&#xD;
        For these reasons, we are proposing a waiver of informed consent for this diagnostic&#xD;
        accuracy and feasibility study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mtb-positive, rifampicin-resistant respiratory specimen identified on Xpert MTB/RIF&#xD;
             Ultra&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Residual SR-sputum mix not retained or not found&#xD;
&#xD;
          -  Patient previously included in the study&#xD;
&#xD;
        Exclusion for diagnostic accuracy and time-to-result endpoints:&#xD;
&#xD;
          -  Insufficient residual SR-sputum mix remaining for Xpert MTB/XDR (&lt;2 ml)&#xD;
&#xD;
          -  Xpert MTB/XDR unsuccessful&#xD;
&#xD;
          -  No second / follow-up specimen received&#xD;
&#xD;
          -  Second / follow-up specimen culture-negative, contaminated or not available&#xD;
&#xD;
          -  Reference standard uninterpretable (phenotyping or WGS)&#xD;
&#xD;
               -  Where phenotypic susceptibility testing results are uninterpretable, specimens&#xD;
                  will still be included in WGS comparison&#xD;
&#xD;
               -  Where WGS results are uninterpretable, specimens will still be included in&#xD;
                  phenotypic susceptibility testing comparison&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adam Penn-Nicholson</last_name>
    <phone>+41227100590</phone>
    <email>adam.penn-nicholson@finddx.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Morten Ruhwald</last_name>
    <phone>+41227100590</phone>
    <email>morten.ruhwald@finddx.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Cox</last_name>
      <phone>+27767169702</phone>
      <email>helen.cox@uct.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Chad Cetner</last_name>
      <phone>+27-82-253-7618</phone>
      <email>chadc@nis.za</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of the Witwatersrand</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley Scott</last_name>
      <email>lesley.scott@wits.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Riffat Munir</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

